Greenberg Michael J, Daily Neil J, Wang Ann, Conway Michael K, Wakatsuki Tetsuro
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, United States.
InvivoSciences Inc., Madison, WI, United States.
Front Cardiovasc Med. 2018 Sep 19;5:120. doi: 10.3389/fcvm.2018.00120. eCollection 2018.
Heart failure is the leading cause of death in the western world and as such, there is a great need for new therapies. Heart failure has a variable presentation in patients and a complex etiology; however, it is fundamentally a condition that affects the mechanics of cardiac contraction, preventing the heart from generating sufficient cardiac output under normal operating pressures. One of the major issues hindering the development of new therapies has been difficulties in developing appropriate model systems of human heart failure that recapitulate the essential changes in cardiac mechanics seen in the disease. Recent advances in stem cell technologies, genetic engineering, and tissue engineering have the potential to revolutionize our ability to model and study heart failure . Here, we review how these technologies are being applied to develop personalized models of heart failure and discover novel therapeutics.
心力衰竭是西方世界的主要死因,因此,对新疗法有巨大需求。心力衰竭在患者中的表现多样,病因复杂;然而,它本质上是一种影响心脏收缩机制的病症,导致心脏在正常工作压力下无法产生足够的心输出量。阻碍新疗法发展的主要问题之一是难以开发出合适的人类心力衰竭模型系统,以重现该疾病中心脏力学的本质变化。干细胞技术、基因工程和组织工程的最新进展有可能彻底改变我们对心力衰竭进行建模和研究的能力。在此,我们综述这些技术如何被应用于开发个性化的心力衰竭模型并发现新的治疗方法。